Fully Human Antibody / TCR Platforms

TCR-mimic Platform

Immunotherapy has advanced significantly, with antibody therapies targeting cell surface or soluble antigens like PD-1 and PD-L1. However, many tumor-associated antigens, such as RAS and P53, are intracellular, limiting antibody effectiveness. T cell receptors (TCRs) can target these intracellular antigens via MHC-antigen-peptide (MAP) complexes, but their low affinity often enables tumor immune evasion.

  • 10+
    TCR-mimic Assets
  • ～150
    Antibody asset partnerships
related resource

on this page

  • Advantages of Biocytogen's TCR-mimic Antibody Platform
  • Discovery of Novel TCR-mimic Antibodies
  • Biocytogen's TCR-mimic Antibodies under Development

Webinars

View All

    Posters

    View All
      Advantages of Biocytogen's TCR-mimic Antibody Platform
      • Biocytogen's unique HLA/RenMab mice, combined with our high-throughput antibody screening platform, enables a one-step process to generate fully human antibodies in vivo that identify human MAPs with high affinity.
      • The antibodies selected through screening have better affinity and specificity than TCRs.
      • The in situ large-fragment replacement and modification in RenMab mice ensures the diversity of antibody sequences.
      • Our discovery process involves high-throughput screening in shortened timelines using the Beacon Optofluidic System and subsequent sequencing.
      • The fully antibody sequences obtained by the TCR-mimic antibody technology platform provide more candidates for subsequent antibody-related drugs, CAR-T, TCR-T and other fields. It provides more intracellular targets for targeted clearance of specific abnormal cells such as tumor cells, infected cells and senescent cells. In addition, TCR-like blocking antibodies can also be utilized to spare cell populations that are attacked by autoimmune disease, so as to avoid damage to normal tissues.
      Novel linker/payload system BLD1102 independently developed by Biocytogen

      Briefly, BLD1102 is a new ADC platform developed by Biocytogen independently.

      • BCPT02 is a novel topoisomerase 1 inhibitor with broad-spectrum and potent tumor killing ability.
      • The uniquely designed cleavable linker has excellent hydrophilicity, making ADCs as hydrophilic as monoclonal antibodies, greatly improving ADC's physiochemical properties.
      • BLD1102-ADCs exhibit good stability in plasma and more potent tumor killing compared to vcMMAE.
      • BLD1102 demonstrated good tolerabilities in preclinical non-human primates.
      Biocytogen's RenTCRmimic-based TCR-mimic Antibody Platform

      TCR-mimic Antibody developed from RenTCRmimic™ mice

      Biocytogen's Fully Human TCRm Antibody Discovery Workflow

      Most traditional antibodies target cell surface antigens (PD-1 and PD-L1, etc) or soluble antigens. However, ideal tumor antigens are often intracellular, (RAS, P53, WT1, etc). Endogenous T cell receptor (TCR) can recognize intracellular antigen/HLA complex, i.e. MHC-antigen-peptide, MAP, to activate T cells against tumor cells. But their affinity to the antigen is low, which often leads to tumor immune escape.

      Biocytogen's TCR-mimic (TCRm) antibody technology platform is designed for the discovery of TCRm antibodies with high affinity and specificity compared with endogenous TCRs.

      Biocytogen's TCR-mimic Antibodies under Development
      Target(s) Immunization
      • Development
      • Hits
        selection         Leads
        selection         Candidate
        selection
      		Preclinical IND
      WT1
      NY-ESO-1
      KRAS G12V/HLA-A03
      KRAS G12V/HLA-A11
      GP100
      MAGEA4
      AFP
      BIRC5
      LMP2